{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:55:50Z","timestamp":1777874150537,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023448","name":"Robert Koch Institut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003107","name":"German Federal Ministry of Health","doi-asserted-by":"publisher","award":["ZMVI5-2514NIK030 \/\/321-4471-02\/137"],"award-info":[{"award-number":["ZMVI5-2514NIK030 \/\/321-4471-02\/137"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128558","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:55:37Z","timestamp":1775800537000},"page":"128558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sex- and age-specific background incidence rates for various medical events in the German population aged\u00a0\u2265\u00a050\u00a0years using a nationwide monitoring system of claims data"],"prefix":"10.1016","volume":"81","author":[{"given":"Wiebe","family":"K\u00fclper-Schiek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Rieck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Keller-Stanislawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"K\u00fcpper-Nybelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Siedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Oberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128558_bb0005","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.vaccine.2024.01.025","article-title":"What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety","volume":"42","author":"Clothier","year":"2024","journal-title":"Vaccine"},{"issue":"9707","key":"10.1016\/j.vaccine.2026.128558_bb0010","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128558_bb0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/INF.0b013e318149dfea","article-title":"Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions","volume":"26","author":"Siegrist","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128558_bb0020","article-title":"Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128558_bb0025","author":"The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance E","year":"2023"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128558_bb0030","first-page":"2015","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128558_bb0035","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.vaccine.2009.10.115","article-title":"Rates of autoimmune diseases in kaiser permanente for use in vaccine adverse event safety studies","volume":"28","author":"Klein","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128558_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5823","article-title":"Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: Nationwide population based cohort study","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128558_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210833","article-title":"Demonstration of background rates of three conditions of interest for vaccine safety surveillance","volume":"14","author":"Wormsbecker","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128558_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-329","article-title":"Estimating background rates of Guillain-Barre syndrome in Ontario in order to respond to safety concerns during pandemic H1N1\/09 immunization campaign","volume":"11","author":"Deeks","year":"2011","journal-title":"BMC Public Health"},{"issue":"42","key":"10.1016\/j.vaccine.2026.128558_bb0055","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1016\/j.vaccine.2023.08.079","article-title":"Background rates of adverse events of special interest for COVID-19 vaccines: a multinational global vaccine data network (GVDN) analysis","volume":"41","author":"Phillips","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128558_bb0060","author":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2026.128558_bb0065","first-page":"3","article-title":"Beschluss und wissenschaftliche Begr\u00fcndung f\u00fcr die Erweiterung der Indikationsimpfempfehlung zur Herpes-zoster-Impfung mit dem adjuvantierten Subunit-Totimpfstoff f\u00fcr Personen \u2265 18 Jahre mit einem erh\u00f6hten Risiko, an Herpes zoster zu erkranken","volume":"45","author":"Koch","year":"2025","journal-title":"Epid Bull"},{"key":"10.1016\/j.vaccine.2026.128558_bb0070","author":"European Medicine Agency"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128558_bb0075","article-title":"Immune-mediated diseases from the point of view of psychoneuroimmunoendocrinology","volume":"11","author":"Ortega","year":"2022","journal-title":"Biology (Basel)"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128558_bb0080","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.17.30521","article-title":"Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015","volume":"22","author":"Rieck","year":"2017","journal-title":"Euro Surveill."},{"issue":"2","key":"10.1016\/j.vaccine.2026.128558_bb0085","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4161\/hv.26986","article-title":"Vaccination coverage among children in Germany estimated by analysis of health insurance claims data","volume":"10","author":"Rieck","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128558_bb0090","first-page":"A271","volume":"6","year":"2011","journal-title":"Dtsch Arztebl"},{"key":"10.1016\/j.vaccine.2026.128558_bb0095","series-title":"ICD-10-GM 2014 Systematisches Verzeichnis: Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme","author":"Graubner","year":"2014"},{"issue":"03","key":"10.1016\/j.vaccine.2026.128558_bb0100","first-page":"1","article-title":"Administrative pr\u00e4valenzen und inzidenzen des diabetes mellitus von 2009 bis 2015","volume":"17","author":"Goffrier","year":"2017","journal-title":"Versorgungsatalasde"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128558_bb0105","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1475-6773.2011.01325.x","article-title":"Estimation of disease incidence in claims data dependent on the length of follow-up: a methodological approach","volume":"47","author":"Abbas","year":"2012","journal-title":"Health Serv Res"},{"key":"10.1016\/j.vaccine.2026.128558_bb0110","series-title":"Routinedaten im Gesundheitswesen \u2013 Handbuch Sekund\u00e4rdatenanalyse: Grundlagen, Methoden und Perspektiven","first-page":"358","article-title":"Krankheitsereignis: Operationalisierung und Falldefinition","author":"Schubert","year":"2014"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128558_bb0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","article-title":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 european healthcare databases - an ACCESS cohort study","volume":"41","author":"Willame","year":"2023","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128558_bb0120","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2471\/BLT.13.135145","article-title":"Measles incidence and reporting trends in Germany, 2007-2011","volume":"92","author":"Takla","year":"2014","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2026.128558_bb0125","first-page":"3","article-title":"Impfquoten bei erwachsenen in deutschland \u2013 aktuelles aus der KV-Impfsurveillance","volume":"49","author":"Rieck","year":"2022","journal-title":"Epidemiologisches Bulletin"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2026.128558_bb0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000369344","article-title":"Estimation of background incidence rates of Guillain-Barre syndrome in Germany - a retrospective cohort study with electronic healthcare data","volume":"43","author":"Hense","year":"2014","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128558_bb0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128558_bb0140","first-page":"593","article-title":"Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database","volume":"20","author":"Vena","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.vaccine.2026.128558_bb0145","first-page":"1","article-title":"Incidence of type 1 and type 2 diabetes before and during the COVID-19 pandemic in Germany: analysis of routine data from 2015 to 2021","volume":"8","author":"Reitzle","year":"2023","journal-title":"Journal of Health Monitoring"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128558_bb0150","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/dc21-1752","article-title":"The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions","volume":"45","author":"Harding","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128558_bb0155","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cpt.2828","article-title":"Safety monitoring of COVID-19 vaccines: perspective from the european medicines agency","volume":"113","author":"Durand","year":"2023","journal-title":"Clin Pharmacol Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600366X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600366X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:07:48Z","timestamp":1777576068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600366X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S0264410X2600366X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128558","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex- and age-specific background incidence rates for various medical events in the German population aged\u00a0\u2265\u00a050\u00a0years using a nationwide monitoring system of claims data","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128558"}}